Featured Resource: Licensing deal with Stalicla SA & Clinical Programme update
Find out more about Evgen's licensing deal with Stalicla and about the current clinical programme Read More
October 12, 2022
Filter by:
Corporate Documents
Corporate Presentations
Scientific Posters & Presentations
Scientific Publications
Date
Title
Download
July 21, 2022
Voting on AGM Resolutions
June 21, 2022
Notice of AGM
July 13, 2021
Voting on AGM resolutions
June 17, 2021
Notice of AGM
February 2, 2021
2021 Placing form of proxy
February 2, 2021
2021 Placing and Open Offer shareholder circular
October 15, 2015
AIM Admission Document
October 12, 2015
Articles of Association
Date
Title
Download
March 23, 2023
Investor Meet Company & ProActive Investor Events Presentation
December 9, 2022
2022 Interim Results Presentation
October 12, 2022
Evgen Pharma Licensing and Clinical Programme Update
July 21, 2022
AGM Presentation – Harnessing the Power of Sulforaphane
January 4, 2022
Corporate Presentation – Harnessing the Power of Sulforaphane
Date
Title
Download
September 27, 2019
Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of Metastatic breast cancer, presented at ESMO 2019
- Sacha Howell et al
March 28, 2019
Novel biomarkers for sulforaphane treated patients in ER+/HER- metastatic breast cancer, presented at ABPP 2019
- Daniel Conole et al
March 25, 2019
STEM Headline Results presentation, 25 March 2019
- Sacha Howell et al
December 4, 2018
STEM Trial: SFX-01 in the Treatment and Evaluation of Metastatic breast cancer, presented at the San Antonio Breast Cancer Symposium 2018
- Sally Ross et al
January 15, 2018
SFX-01 targets STAT3 signalling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours, presented at the UK Interdisciplinary Breast Cancer Symposium 2018
- Bruno Simoes et al
Date
Title
Download
March 27, 2023
SFX-01 in the treatment of rhabdomyosarcoma: Preclinical results in cellular models
- Simona Camero et al
October 26, 2021
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma, Pharmaceuticals, 26 October 2021
- Alessandro Colapietro et al
September 16, 2021
Effect of SFX-01 on proliferation of human glioblastoma cell lines, BioRxiv, 16 September 2021
- Euphemia Leung et al
July 14, 2020
Can Activation of NRF2 Be a Strategy against COVID-19? Trends in Pharmacological Sciences, September 2020
- Antonio Cuadrado et al
May 30, 2020
Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer, Nature Oncogene, 20 May 2020
- Bruno Simoes et al
October 1, 2019
Final Results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC), Annals of Oncology, 1 October 2019
- Sacha Howell et al
February 5, 2019
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases, Nature Reviews Drug Discovery, 5 February 2019
- Antonio Cuadrado et al
October 28, 2014
Sulforaphane treatment of autism spectrum disorder (ASD), PNAS, 28 October 2014
- Kanwaljit Singh et al